Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion

被引:54
作者
Cryan, JF
Gasparini, F
van Heeke, G
Markou, A
机构
[1] Novartis Pharma AG, Novartis Inst Biomed Res, Neurosci Dis Area, CH-4002 Basel, Switzerland
[2] Novartis Inst Biomed Res, Resp Dis Area, Horsham, W Sussex, England
[3] Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA
关键词
VENTRAL TEGMENTAL AREA; AMINOBUTYRIC ACID(B) RECEPTORS; INDUCED DOPAMINE RELEASE; STRESS-INDUCED RELAPSE; BRAIN REWARD FUNCTION; SMOKING-CESSATION; SEEKING BEHAVIOR; COCAINE-SEEKING; NUCLEUS-ACCUMBENS; DRUG-ADDICTION;
D O I
10.1016/S1359-6446(03)02890-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Smoking is a major health problem and is propelled, at least in part, by the addictive properties of nicotine. Two types of pharmacological therapies have been approved for smoking cessation by the US Food and Drug Administration. The first therapy consists of nicotine replacement, substituting the nicotine from cigarettes with safer nicotine formulations. The second therapy is bupropion (Zyban((R))), an atypical antidepressant, whose use has raised much debate as to how a non-nicotine-based agent can aid in smoking cessation. This review focuses on recent advances that could lead to the development of improved novel pharmacological treatments. These strategies focus on altering reward processes in the brain by modulating various neurotransmitter systems: the most promising include dopamine D-3 receptor antagonists, noradrenaline reuptake inhibitors, GABA(B) receptor agonists, metabotropic glutamate 5 (mGluRS) receptor antagonists, cannabinoid CB1 receptor antagonists, and corticotropin releasing factor (CRF) 1 receptor antagonists.
引用
收藏
页码:1025 / 1034
页数:10
相关论文
共 89 条
[61]   Bupropion occupancy of the dopamine transporter is low during clinical treatment [J].
Meyer, JH ;
Goulding, VS ;
Wilson, AA ;
Hussey, D ;
Christensen, BK ;
Houle, S .
PSYCHOPHARMACOLOGY, 2002, 163 (01) :102-105
[62]  
MUNAFO M, 2003, SMOKING CESSATION MA
[63]   Intervention for relapse to smoking: The Lung Health Study restart programs [J].
Murray, RP ;
Voelker, HT ;
Rakos, RF ;
Nides, MA ;
McCutcheon, VJ ;
Bjornson, W .
ADDICTIVE BEHAVIORS, 1997, 22 (02) :281-286
[64]   The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice [J].
Paterson, NE ;
Semenova, S ;
Gasparini, F ;
Markou, A .
PSYCHOPHARMACOLOGY, 2003, 167 (03) :257-264
[65]   Increased GABA neurotransmission via administration of gamma-vinyl GABA decreased nicotine self-administration in the rat [J].
Paterson, NE ;
Markou, A .
SYNAPSE, 2002, 44 (04) :252-253
[66]  
PATERSON NE, IN PRESS PSYCHOPHARM
[67]   Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist [J].
Pilla, M ;
Perachon, S ;
Sautel, F ;
Garrido, F ;
Mann, A ;
Wermuth, CG ;
Schwartz, JC ;
Everitt, BJ ;
Sokoloff, P .
NATURE, 1999, 400 (6742) :371-375
[68]   Positive allosteric modulators for γ-aminobutyric AcidB receptors open new routes for the development of drugs targeting family 3 G-protein-coupled receptors [J].
Pin, JP ;
Parmentier, ML ;
Prézeau, L .
MOLECULAR PHARMACOLOGY, 2001, 60 (05) :881-884
[69]  
Preti A, 2000, Curr Opin Investig Drugs, V1, P241
[70]  
Rasmussen K, 2000, J PHARMACOL EXP THER, V294, P688